REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. (RGNX) on June 7, 2022, covering events that occurred on June 3, 2022. The filing primarily addresses corporate governance matters, including the election of a new director and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on governance and voting results rather than financial performance metrics.
Material Changes and Governance Events
- Director Election: The Board elected Jennifer Zachary as a Class I director and member of the Audit Committee, effective June 3, 2022. Her term expires at the 2025 annual meeting.
- Compensation for New Director: Ms. Zachary received an initial equity award with a grant date fair value of $550,000 (75% stock options, 25% RSUs). The option exercise price is $22.84 per share. She will receive an annual retainer of $45,000 plus an additional $10,000 for Audit Committee service.
- Annual Meeting Results:
- Proposal 1 (Director Election): Allan M. Fox and Alexandra Glucksmann, Ph.D., were elected as Class I directors. Significant votes were withheld for both nominees (approx. 21% and 16% respectively).
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP with overwhelming support (99.3% for).
- Proposal 3 (Say-on-Pay): Stockholders approved the executive compensation advisory proposal with 96.7% voting for.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, operational outlook, or new risk factors. It notes that Ms. Zachary has entered into a standard indemnification agreement with the Company. No unusual items or contingencies were reported in this specific filing.
Key Facts for Investor Verification
- Verify the voting percentages for the Class I director nominees, as a notable portion of votes were withheld.
- Confirm the vesting schedule details for the new director's equity award, specifically the 36-month vesting for options and the 3-year cliff vesting for RSUs.
- Review the definitive proxy statement (Schedule 14A filed April 7, 2022) for detailed background on the director nominees and executive compensation.
- Note that this filing does not update the company's financial position; refer to the most recent 10-Q or 10-K for financial data.